[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiac-valve-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiac-valve-disease":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,48,82,109,141,163,191],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100527158","phase-4-prothrombin-complex-concentrate-vs-fresh-frozen-plasma-in-goal-directed-bleeding-management-in-cardiac-surgery-100527158",false,"NCT06144125","Prothrombin Complex Concentrate vs Fresh Frozen Plasma in Goal-directed Bleeding Management in Cardiac Surgery","Prothrombin Complex Concentrate and Fresh Frozen Plasma in Viscoelastic Test-based Goal-directed Bleeding Management in Cardiac Surgery","Inclusion Criteria:\n\n* patients undergoing cardiac surgery\n\nExclusion Criteria:\n\n* thrombocytopenia\n* oral anti-coagulant\n* anti platelet agents",true,"ALL","20 Years","75 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","The primary endpoint of this study is the completion time of hemostasis treatment when administered Fresh frozen plasma (FFP) and frozen powder coagulation factor concentrate (PCC) in goal-directed bleeding management for cardiac surgery.",[28],"Cardiac Valve Disease",[30,31,32,33,34],"prothrombin complex concentrate","fresh frozen plasma","coagulation","bleeding","cardiac surgery","RECRUITING","2026-06-15",{"date":38,"type":39},"2026-06-17","ACTUAL",{"date":41,"type":39},"2026-03-27",{"date":43,"type":22},"2026-10-30",{"name":45,"class":46},"Konkuk University Medical Center","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":19,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":47},"100541926","antibacterial-tactics-based-on-presepsin-level-in-thoracic-aorta-surgery-patients-100541926","NCT06336213","Antibacterial Tactics Based on Presepsin Level in Thoracic Aorta Surgery Patients","Changes in Antibacterial Therapy Based on Perioperative Dynamics of Presepsin During Reconstructive Thoracic Aorta Surgery","Inclusion Criteria:\n\nThoracic aorta aneurysm\u002Fdissection\n\nExclusion Criteria:\n\nBlood sample hemolysis","18 Years",{"count":57,"type":22},50,[59],"NA","According to the literature, presepsin was recommended not only as an effective indicator in the diagnosis of sepsis in intensive care units, but also as a reliable prognostic marker of postoperative inflammatory processes in cardiac surgery. Previous study carried out in Petrovsky NRCS related to biomarkers in cardiac surgery and presepsin in particular showed good sensitivity in infection complications prognosis.",[62,28,63,64],"Aortic Aneurysm and Dissection","Thoracic Aortic Aneurysm","Thoracic Aortic Dissection",[66,67,68,69,70,71,72,34],"biomarkers","presepsin","complications","aortic arch","aorta","aortic aneurysm","ascending aorta","2026-01-28",{"date":75,"type":39},"2026-01-29",{"date":77,"type":39},"2024-01-23",{"date":79,"type":22},"2027-02-15",{"name":81,"class":46},"Petrovsky National Research Centre of Surgery",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":91,"conditions":92,"keywords":93,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":108},"100521236","cardiac-biomarkers-for-the-quantification-of-myocardial-damage-after-cardiac-surgery-100521236","NCT06066970","Cardiac Biomarkers for the Quantification of Myocardial Damage After Cardiac Surgery","RORSCHACH","Inclusion Criteria:\n\n* Indication for isolated aortic or mitral valve surgery\n* Written informed consent\n* Age ≥ 18 years\n\nExclusion Criteria:\n\n* Presence of coronary artery disease (excluded within the last 6 months)\n* Allergy to gadolinium\n* Cochlear implant\n* Deep brain stimulation\n* Individual factors excluding the performance of an MRI (e.g. claustrophobia of the patient)\n* Significantly reduced renal function (GFR \\< 30ml\u002Fmin)\n* Perioperative complications that may lead to myocardial damage (discontinuation of the study for the patient and exclusion from the analysis after primary study inclusion)\n* Need for extension of surgery (additional procedures on other heart valves, aorta, myocardium, or similar; exclusion after primary study inclusion possible)\n* Pregnancy or lactation",{"count":21,"type":22},"OBSERVATIONAL","The aim of the study is to clarify whether the perioperative release of the cardiac biomarkers troponin I, troponin T and CK-MB consistently correlate with visualizable myocardial damage, and to what extent these biomarkers are comparable by means of their kinetics and dynamics.\n\nDue to the uncertainty regarding the validity of cardiac biomarkers in the diagnosis of myocardial infarction, the answer to these questions could have a considerable influence on internationally valid guidelines and definitions. International studies, especially in the field of coronary surgery and coronary artery disease treatment refer to these definitions, in particular, the adequate treatment of affected patients is directly dependent on them.",[28],[94,95,96,97,98],"Biomarker","Troponin","CK-MB","Perioperative Myocardial Infarction","LGE-cMRI","2025-09-23",{"date":101,"type":39},"2025-09-26",{"date":103,"type":39},"2023-09-05",{"date":105,"type":22},"2025-12-31",{"name":107,"class":46},"Jena University Hospital",5,{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":23,"phases":118,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":137,"leadSponsor":139,"locationsCount":47},"100556147","impact-of-nicotinamide-riboside-nr-on-kidney-function-in-patients-undergoing-cardiac-surgery-100556147","NCT06521307","Impact of Nicotinamide Riboside (NR) on Kidney Function in Patients Undergoing Cardiac Surgery","Impact of Nicotinamide Riboside (NR) on Kidney Function in Patients Undergoing Cardiac Surgery.A Randomized Controlled Pilot Study","AKI-RCT","Inclusion Criteria:\n\n* Heart valve replacement surgery\n* Sign of informed consent\n\nExclusion Criteria:\n\n* Allergy to any of the components\n* Platelet count less than 100,000\n* Weight less than 50Kg or over 100Kg\n* Any type of infectious disease (e. g, Endocarditis)\n* GFR less or equal to 15ml\u002Fmin\u002Fm2 or with renal replacement therapy\n* IV or oral contrast medium 72 hrs prior recruitment\n* LRA 7 days prior to surgery",{"count":21,"type":22},[59],"Acute kidney injury (AKI) associated with cardiac surgery is the most important complication in adult patients undergoing open heart surgery and is associated with increased mortality and morbidity. In patients in intensive care units, it is the second most common type of AKI after AKI secondary to sepsis. There is currently no specific treatment for AKI. Supportive measures include renal support therapy for patients with severe AKI, and mortality in this subgroup of patients exceeds 50%. Increasing NAD+ with niacinamide has been shown to prevent various etiologies of experimental AKI in mice, and an early pilot study has shown both increased NAD levels following administration of nicotinamide riboside with pterostilbene NPRT and the safety of niacinamide in patients undergoing cardiac surgery.",[121,28],"Acute Kidney Injury",[123,124,125,126,127,128,129,130,131],"Nicotinamide Riboside","NAD+","NADH","SIRT1","AKI","Cardiac surgery","TIMP-2","IGFBP7","NGAL","NOT_YET_RECRUITING","2024-07-24",{"date":135,"type":39},"2024-07-25",{"date":133,"type":22},{"date":138,"type":22},"2026-07-24",{"name":140,"class":46},"Instituto Nacional de Cardiologia Ignacio Chavez",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":23,"phases":148,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":47},"100516205","the-effects-of-360-degree-virtual-reality-on-pre-procedural-anxiety-in-patients-awaiting-elective-cardiac-surgery-involving-a-sternotomy-100516205","NCT06001489","The Effects of 360-degree Virtual Reality on Pre-procedural Anxiety in Patients Awaiting Elective Cardiac Surgery Involving a Sternotomy","Inclusion Criteria:\n\n* Patients awaiting elective cardiac surgery involving a sternotomy\n* 18 years or older\n\nExclusion Criteria:\n\n* Under the age of 18\n* History of previous cardiac surgery\n* (concomitant) aortic surgery\n* Cardiac surgery for congenital heart defects\n* Hearing or visual impairments\n* Language barriers (inability to understand, speak or read Dutch)\n* History of severe mental or psychiatric disorders",{"count":21,"type":22},[59],"Rationale: Patients awaiting cardiac surgery can experience pre-procedural anxiety. This anxiety is associated with increased analgesic needs, increased risk of mortality and prolonged recovery time. Adequate patient education can help diminish pre-procedural anxiety and minimize postoperative complications. Recent studies have demonstrated that Virtual Reality (VR) can function as a useful tool to diminish pre-procedural anxiety in several medical fields. Especially 360 degree VR could familiarize patients with their clinical pathway. Nevertheless, limited to no research on the application of 360 degree VR has been conducted in the context of cardiothoracic surgery yet.\n\nObjective: The aim of this study is to explore the effects and possible benefits of 360 degree VR on pre-procedural anxiety in patients awaiting elective cardiac surgery involving a sternotomy, compared to standard forms of patient education.\n\nStudy design: Single-center, randomized controlled trial\n\nStudy population: Patients aged 18 or older awaiting elective cardiac surgery involving a sternotomy.",[28,151,152,153],"Aortic Valve Disease","Mitral Valve Disease","Tricuspid Valve Disease","2024-07-09",{"date":156,"type":39},"2024-07-10",{"date":158,"type":39},"2023-07-01",{"date":160,"type":22},"2024-12",{"name":162,"class":46},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":170,"targetDuration":172,"studyType":90,"phases":4,"briefSummary":173,"conditions":174,"keywords":175,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":190},"100439457","corcym-mitral-aortic-and-tricuspid-post-market-study-in-a-real-world-setting-100439457","NCT05002543","CORCYM Mitral, Aortic aNd Tricuspid Post-maRket Study in a reAl-world Setting","MANTRA","Inclusion Criteria:\n\n* Signed and dated approved Informed Consent\n* Subject is willing and able to comply with the follow up schedule of the protocol\n* Eligible for treatment with CORCYM aortic, mitral and\u002For tricuspid products as outlined in the applicable Instructions for Use (IFU)\n\nExclusion Criteria:\n\n* Subject is already participating to another clinical investigation that could confound the results of this clinical investigation.\n* Subject has a life expectancy ≤ 12 months\n* Subject has contraindications to the use of CORCYM aortic, mitral and\u002For tricuspid devices as outlined in the applicable Instructions For Use (IFU)",{"count":171,"type":22},2150,"10 Years","MANTRA is a prospective, multiple-arm, multi-center, global, post-market clinical follow-up study. The main objective is to monitor ongoing safety and performance of the CORCYM devices and accessories used for aortic, mitral and tricuspid valvular diseases in a real-world setting.\n\nCorcym S.r.l., is a medical device manufacturer with a broad product portfolio for cardiac surgeons, offering solutions for the treatment of aortic, mitral and tricuspid valve disease.\n\nThe MANTRA Master Plan (Master Protocol) is intended as an overarching Umbrella Protocol that allows multiple sub-studies to be added, as needed. The Umbrella Master Protocol concept offers an excellent solution to provide post-marketing clinical follow-up information on the entire cardiac surgery heart valve portfolio of the sponsor in a common database, including corelab assessment of hemodynamic and structural performance, annular motion and Dynamics for one of the products.\n\nCurrently, three sub-studies are planned:\n\n* MANTRA - Aortic Sub-Study\n* MANTRA - Mitral\u002FTricuspid Sub-Study (Excluding Memo 4D)\n* MANTRA - Memo 4D Sub-Study",[28],[176,177,178,179],"Aortic Valve Replacement","Mitral Valve Replacement","Mitral Valve Repair","Tricuspid Valve Repair","2024-03-05",{"date":182,"type":39},"2024-03-06",{"date":184,"type":39},"2021-06-29",{"date":186,"type":22},"2035-12-31",{"name":188,"class":189},"Corcym S.r.l","INDUSTRY",52,{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":197,"eligibilityCriteria":198,"healthyVolunteers":11,"sex":17,"minAge":199,"maxAge":200,"enrollmentInfo":201,"targetDuration":203,"studyType":90,"phases":4,"briefSummary":204,"conditions":205,"keywords":211,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":225},"100478155","european-multicentre-registry-of-percutaneous-paravalvular-leak-closure-100478155","NCT05506293","European Multicentre Registry of Percutaneous Paravalvular Leak Closure","European Multicentre Registry of Percutaneous Paravalvular Leak Closure - EuroPVL Study","EuroPVL","Inclusion Criteria:\n\n* ≥16 years of age No opposition from the patient or the representative of the parental authority if the patient is a minor Patient referred for a percutaneous paraprosthetic leak closure procedure\n\nExclusion Criteria:\n\n* \\\u003C 16 years old Refusal of the patient to participate in the observatory or of the legal representative if the patient is a minor","16 Years","110 Years",{"count":202,"type":22},400,"2 Years","Paraprosthetic cardiac valve leaks are a progressive complication after after surgical or percutaneous heart valve replacement. These leaks can lead to heart failure and\u002For life-threatening hemolysis.\n\nPercutaneous closure of para-prosthetic leaks has been developed as an alternative to surgery in high-risk patients. These procedures remain technically challenging with a significant risk of failure and complications, but this risk is improved since the development of dedicated prostheses and the increased experience of the operators. The data in the literature concerning percutaneous leak closure remain limited and disparate and mostly retrospective.The impact of the procedures on the quality of life of patients is not known. Beyond the technical aspects and the follow-up of major cardiovascular events, investigators also wonder what is the impact of these procedures on the quality of life of patients. Investigators hypothesize that even a partial reduction in paraprosthetic leakage may be associated with an improvement in quality of life through reduction of transfusion needs and\u002For reduction of dyspnea. A prospective study is warranted to assess the technical and clinical and clinical results of these procedures, together with the evaluation of the the possible benefit on the quality of life of the patients.",[28,206,207,208,209,210],"Paravalvular Aortic Regurgitation","Paravalvular Mitral Regurgitation","Paravalvular Leak","Quality of Life","Outcomes",[212,213,214,215],"paravalvular leak","percutaneous intervention","quality of life","outcomes","2022-08-16",{"date":218,"type":39},"2022-08-18",{"date":220,"type":39},"2020-01-01",{"date":222,"type":22},"2026-07-01",{"name":224,"class":46},"Centre Chirurgical Marie Lannelongue",33]